Twitter in Zimbabwe informally known as Zwitter, was abuzz with discussions on the new HIV cure discovered by PHD ministries leader, prophet Magaya. Although some have welcomed the news and even urged the ministry of health to carry out tests and hopefully also embrace the drug, the reality is unfortunately that missteps were made in the process of bringing the drug from discovery to marketing. In this article we compare the real proper path followed by a drug from the test tube up until it reaches the market with that described by prophet Magaya for his new drug. Some of the missteps are glaring. Take a look!
How does a new medicine move: From test tube to the market
Step 1: Drug Discovery
The
first step in the process would be the discovery of the drug. In the
case of prophet Magaya that would correspond to his prophetic discovery
of the herb.
Step 2: Pre-Clinical Research
This
phase involves basic laboratory testing to verify that the drug is safe.
the drug may at this stage be sued on animals. Safety is very important
because drugs must not harm the persons taking them but in the case of
the new cure this part is not well described neither did the journalists
who attended request this information.
Step 3: Clinical Testing
In
this phase the drug is tested on human paying particular attention to
safety and efficacy. Evidence for this stage is best collected using
the randomized control trial. This design features random assignment of
participants into at least one intervention group and a control group, administration of the test drug to the intervention group and standard of care drug or placebo to the control group. By comparing outcomes between control groups evidence is generated for
safety and efficacy of the drug. In the case of prophet Magaya we did
not hear about the existence of a control group. Although we heard about
the improvement of CD4 in two weeks, there was no comparative. To make valid conclusions on the efficacy of the drug more persuasive evidence is
needed.
Step 4: Approval Stage
All the evidence
collected in stage is submitted to a competent drug regulatory body, the
Medicine Control Authority of Zimbabwe (MCAZ) in our case. The purpose
is for professionals there to thoroughly review the evidence and
determine if it should be approved or not. In the case of prophet Magaya
we only heard about plans that the ministry of health will test the new
drug. However one can never be sure as the ministry of health issued a
statement today (29/10) distancing themselves from the drug. They even
urged patients to continue taking their ARVs.
Step 5: Marketing And Distribution
It
appears that this is the only stage that prophet Magaya started with
this stage. In the normal scheme of things this should be the last
stage.
Conclusion
While those that welcome the drug as it was introduced, charge that those opposed are suffering from an imaginary sickness called 'pull him down' syndrome we have made clear that the process of introducing was flawed if not non existent. We urge members of PLHIV, advocacy groups to stay clear of this new drug. Its not only that the drug may pose side effects such as renal failure or other internal organ failure but it may place substantial financial constraints on patients in return for no real benefits. The ministry of health has also already released a statement urging patients to stick to their usual ART medication.
Comments
Post a Comment